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Abstract: The diagnosis and treatment of urinary tract infections (UTIs) remain challenging due to the
lack of convenient assessment techniques and to the resistance to conventional antimicrobial therapy,
showing the need for novel approaches to address such problems. In this regard, nanotechnology has
a strong potential for both the diagnosis and therapy of UTIs via controlled delivery of antimicrobials
upon stable, effective and sustained drug release. On one side, nanoscience allowed the production
of various nanomaterial-based evaluation tools as precise, effective, and rapid procedures for the
identification of UTIs. On the other side, nanotechnology brought tremendous breakthroughs
for the treatment of UTIs based on the use of metallic nanoparticles (NPs) for instance, owing to
the antimicrobial properties of metals, or of surface-tailored nanocarriers, allowing to overcome
multidrug-resistance and prevent biofilm formation via targeted drug delivery to desired sites of
action and preventing the development of cytotoxic processes in healthy cells. The goal of the current
study is therefore to present the newest developments for the diagnosis and treatment of UTIs based
on nanotechnology procedures in relation to the currently available techniques.
Keywords: urinary tract infections; multidrug resistance; surface-tailored nanomedicines; diagno-
sis; therapy
1. Introduction
The urinary system is the most vital organ system, responsible for the drainage of
urine and for the maintenance of homeostasis [1] via regulation of the blood volume,
pressure, and pH and of metabolites and electrolytes [2]. The urinary system comprises the
kidneys removing wastes and water from the blood in the form of urine [3] that is carried
towards the bladder where it gets stored before leaving the body via the urethra [4].
Infections in any part of the urinary system lead to the development of urinary tract
infections (UTIs) [4,5]. UTIs are considered as one of the most common infections caused
by bacteria, with 150 million people annually affected worldwide [6]. UTIs can be char-
acterized as complicated or uncomplicated [7]. Complicated UTIs are mostly comprised
of infections associated with compromised urinary tract and immune system [7]. Com-
mon diseases associated with complicated UTIs include neurological impairment-based
urinary obstruction, urinary retention, and immunosuppression, renal transplantation,
renal failure, pregnancy, or foreign bodies such as biofilms, calculi, catheters, and other
devices [8]. Catheter-associated UTIs (CAUTIs) are linked to increased morbidity and
mortality and are the most common origin of secondary bloodstream infections [9,10]. Non-
complicated UTIs, the most prevalent forms of UTIs, are not based on any neurological,
structural, nor physiological defects of the urinary tract [11], characteristically affecting
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women, children, and old patients. They are divided into upper tract UTIs in the nephron
(pyelonephritis) and lower tract UTIs (cystitis). The most prominent etiological risk factors
for uncomplicated UTIs are chronic UTIs, sexually transmitted UTIs, vaginal infections,
diabetes, obesity, and genetics [12,13]. UTIs are mostly caused by both Gram-positive
and Gram-negative bacteria and by some fungi. Uropathogenic Escherichia coli (UPEC)
is the only common causative agent in the case of both complicated and uncomplicated
UTIs [14,15]. Peculiar microbes involved in the pathogenesis of complicated UTIs also
include Enterococcus spp., Klebsiella pneumonia, Staphylococcus aureus, Pseudomonas aerug-
inosa, and Candida spp. [16]. Uncomplicated UTI pathogenesis also steeps progressively
due to pathogenic Klebsiella pneumoniae, Staphylococcus saprophyticus, Enterococcus faecalis,
group B Streptococcus (GBS), Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus,
and Candida spp. [17]. The basic mechanism involved in the pathogenesis of UTI is the
adherence of specific virulence factors residing on bacteria in the urethra followed by
colonization and further movement of the pathogen in the bladder using its appendages
(flagella and pili) [18]. After attachment of the pathogens in the bladder, complexed
host–pathogen interactions then occur, bringing the disease to advance stages. UPEC
also develops biofilms-based intracellular bacterial communities (IBCs) as a protection
against host immune responses and to overcome bacterial resistance [19]. UTIs result in
compromised socioeconomical factors and health, affecting the quality life of affected indi-
viduals [20]. Currently, medications used for UTIs include trimethoprim sulfamethoxazole,
ciprofloxacin, ampicillin [21], and combined antibiotic therapy to address the multidrug-
resistance (MDR) features of virulent bacteria [22]. Vaccines targeting bacterial adhesions
and bacterial toxins are also available [23,24]. Nevertheless, all these modalities are associ-
ated with an increased economic burden, non-patient compliance, and need for targeted
delivery, and most importantly with the involvement of virulent factors in bacterial genes
causing MDR, with the emergence of even more resistant genes, making the treatment of
UTIs particularly arduous [25].
The diagnosis of UTIs initially requires a complete disease and medication history, fol-
lowed by the physical examination of the pelvic region and the assessment of uropathogens
in urine samples using various diagnostic approaches [26]. Laboratory diagnostic tests
for UTIs include urinalysis, with an aim to reduce the dose of recommended antibiotics.
Microscopic analysis of urine is also performed to diagnose the presence of certain mi-
crobes [27]. Culturing method is another standard diagnostic test to detect bacteria [28].
Moreover, the isothermal calorimetry technique is based on the evaluation of the metabolic
rates of living microorganisms and microbes. Other conventional and common diagnostic
techniques for UTIs include spectroscopic analysis such as Raman spectroscopy, Fourier
transform infrared spectroscopy (FTIR), and UV spectroscopy [29,30]. Immunological
diagnostic techniques like latex agglutination, enzymatic and coagulation assays are also
useful in detecting antibodies and antigens of bacteria in the samples of UTI patients [26].
The diagnosis of UTIs is challenging owing to the vast existence of gaps accompanying
over-testing, over-diagnosis, over-treatment, non-specificity, and heterogeneous nature of
uropathogens [26,31].
Nanomaterial drug delivery is advantageous compared with conventional therapy
because of enhanced specificity in targeting cells, altered pharmacokinetics as well as
increased bioavailability, controlled drug release, increased solubilization of hydrophobic
drugs, synergistic combinatorial chemistry, and enhancement in drug delivery [32–36].
Nanomaterials can exert their innate antimicrobial action, and synthesizing NPs while
conjugating them to antimicrobials may lead to synergistic antibacterial actions, with cost-
effectiveness and higher stability for a longer period [37]. Antimicrobial NPs for UTIs are
mostly based on metals (gold - Au, silver - Ag, titanium NPs) and on metal-based oxides
(zinc oxide-ZnO-NPs) [37–44]. All metal and metal-based oxide NP damage the pathogenic
microorganisms by various mechanisms of photothermolysis, generating reacting oxygen
species (ROS), damaging the cell wall and cell components of pathogens, and interfering
with normal enzymatic activities and DNA synthesis [45].
Nanomaterials 2021, 11, 546 3 of 21
The use of metallic NPs has several limitations such as the presence of hazardous
wastes, the difficulty in scale-up production, instability, aggregation, and the use of expen-
sive organometallic NPs [46,47]. To overcome these issues, green NP synthesis is being
developed based on the use of natural extracts by exploring biological components, es-
sential phytochemicals like flavonoids, terpenoids, alkaloids, phenols, and aldehydes as
reducing agents and solvent systems. Moreover, to achieve surface functionalization and
receptor-targeted action, the NP surface may be engineered with various biocompatible
ligands, resulting in environmental remediation in terms of removing pollutant dyes and
heavy metals [48–50].
Several nanoparticle-based antimicrobials are used against UTIs such as surfactant-
based vesicles, nanoemulsions, and polymeric NPs like chitosan NPs [51,52]. Chitosan NPs
have the ability to bind with negatively charged bacterial membranes and to increase their
permeability. Carbon-based NPs and nitric oxide (NO)-releasing NPs can generate reactive
nitrogen species (RNS) that also damage the bacterial membrane [53,54].
To overcome the limitations of conventional diagnostic methods for UTIs, a significant
number of nanotechnology-based bioassays are highly effective [55–60]. One of these
important techniques is optical imaging based on differences in contrast agents between
different tissues. The Au nanorods are specific contrast agents, aiming at higher absorbance
and scattering light and playing a promising role in damaging bacteria [61]. Similarly,
magnetic NPs are required for precise quantification and targeting of pathogenic microbes.
Probes based on Au NPs are highly effective and sensitive in detecting microbes [62–67].
Au nanowires arrays get attached with Escherichia coli antibodies to detect the peculiarity
of UTIs [68]. MDR bacteria can be distinguished from non-resistant bacteria using Raman
spectroscopic fingerprints. Moreover, the metabolic activity and antimicrobial suscep-
tibility of pathogens can be evaluated via Con-A-conjugated supermagnetic iron oxide
(SPIO) nanosensors [69]. Keeping in mind all the efforts related to the synthesis of novel
nanomaterials and the investigation of their potential in bioapplications [39,40,70–72], we
next review the nanomaterials applied to the diagnosis and treatment of UTIs.
2. Current Approaches for UTI Diagnosis and Biomarkers
UTIs are the most prevalent infections in persons of any age but especially in elderly
people [73–75]. Owing to the high incidence and recurrence of UTIs and to the worldwide
rise in antibiotic-resistant bacteria, both the diagnosis and treatment of lower and upper
UTIs are becoming more difficult in clinical settings. There are also inexplicable or asymp-
tomatic clinical effects of UTIs. Due to the possibility of septicemia and long-term effects,
an early diagnosis of UTIs is critical [76–79].
The diagnosis of UTIs is currently focusing on the evidence of clinical symptoms
combined with findings of the nitrite strip test (presence of urinary bacteria) and with
an estimation of the number of white blood cells in urine [80,81], as UTI diagnosis in
urine culture is time-consuming and costly [82,83]. Considerable efforts have been lately
directed to evidence novel UTI biomarkers for diagnosis purposes. Several promising
serum and urine biomarkers of UTIs like leukocyte esterase, heparin-binding protein, C-
reactive protein (CRP), procalcitonin, lactoferrin, interleukins, C-reactive protein, elastase
alpha (1)-proteinase inhibitor, secretory immunoglobulin A, heparin-binding protein, α-1
microglobulin (α1Mg), xanthine oxidase, soluble triggering receptor expressed on myeloid
cells-1, myeloperoxidase, and tetrazolium nitroblue test (TNB) gained much attention in
recent years [81]. The challenging problem is to quantitatively estimate these biomarkers
when present at low concentrations. Specific and accurate identification of infectious
pathogens in the healthcare industry is the key feature to improved patient care, select
empirical treatment, and avoid the transmission of infections. Therefore, various diagnosis
methods have been suggested for UTIs. Some may have slower responses, others prolonged
response time, and some may have less precision while some may be too costly [84–87].
Nanotechnology may have the potential to overcome these issues and to increase the
precision of the existing approaches [88,89].
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3. Diagnosis of UTIs by Nanotechnology
UTIs are among the most common bacterial infections, affecting about 50% of the
population at least once in their lives. If UTIs are left undiagnosed and not properly
handled, they may have deadly consequences. Additionally, finding a rapid, early, and
reliable approach for the identification of uropathogens can be valuable in the clinical
phase. Nanoscience is a highly developed area with tremendous scientific interest due to
its numerous potential applications in the biomedical area [90]. To overcome the problems
caused by traditional diagnosis approaches, nanomedicine can be combined with these
methods for better management of UTIs. Nanostructures are more effective in prevent-
ing toxicity and resistance and reducing the costs of more traditional methods [91–94].
The current UTI diagnosis methods and nanotechnological approaches are presented in
Figure 1.
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sponse time and improved precision and accuracy, photoluminescence (PL)-based bio-
sensors attracted more attention in recent years [95–98]. Concerning this, Vasudevan et 
al. [95] developed a nanosensor based on cysteamine-attached ZnO NPs (ZnO-Cys) for 
the identification of N-acyl-homoserine lactones (AHLs) Gram-negative bacteria. AHLs 
are responsible for the activation of pathogenicity in humans. ZnO NPs were prepared 
using a microwave-assisted approach with good sensitivity (97%) and a linear detection 
area of 10–120 nM in artificial urine media. The nanosensor was certified using the 
AHLs created by Pseudomonas aeruginosa (MCC3101) in real-time investigation, support-
ing their overall sensitivity and specificity. 
In an attempt to early diagnose UTIs, a portable bacteria-grabbing nanochip based 
on surface-enhanced Raman scattering (SERS) was generated by Yang et al. [99] to detect 
three species of uropathogens (Proteus mirabilis PRM1, Escherichia coli CFT 073, Pseudo-
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As mentioned above, the existing approaches of urinalysis are complex and time-
consuming and they lack both accuracy and precision [95]. Due to their fast response
time and improved precision and accuracy, photoluminescence (PL)-based biosensors
attracted more attention in re ent years [95–98]. Concerning this, Vasudevan et al. [95]
devel ped a anose sor based on cysteamine-attached ZnO NPs (ZnO-Cys) for the iden-
tification of N-acyl-homoserine lacto s (AHLs) Gram-negative bacteria. AHLs are re-
sponsible for t e activation of pathogenicity in humans. ZnO NPs were prepared using a
mic owave-assisted ap roach with good sensitivity (97%) and a linear detection area of
10–120 nM in artifici l urine media. The nanosensor was certified using the AHLs created
by Pseudomonas er gi osa (MCC3101) in real-time investigation, supporting their overall
sensitivity and p cificity.
In an attempt to early diagnose UTIs, a portable bacteria-grabbing nanochip based on
surface-enhanced Raman scattering (SERS) was generated by Yang et al. [99] to detect three
species of uropathogens (Proteus mirabilis PRM1, Escherichia coli CFT 073, Pseudomonas aerug-
inosa PAO1) directly from the urine sample medium. The chip was first functionalized
with NH3+ groups for improved electrostatic adsorption of bacteria with a negative charge.
Once the bacteria were captured by the chip, Ag NPs were used to achieve Raman finger-
print spectra of the bacteria. The SERS-based chip detected three species of UTI bacteria
at low concentration (105 cells/mL) by discriminant analysis (chemometric approach).
Additionally, without any sample pre-treatment, the nanochip provided the fingerprint
Nanomaterials 2021, 11, 546 5 of 21
information of the bacteria directly from artificial urine and Luria–Bertani (LB) culture
medium.
In another study, Alhogail et al. [100] created a rapid, adaptive, and precise colorimet-
ric nanosensor based on magnetic NPs (MNPs) for the identification of Pseudomonas aerugi-
nosa in vivo. The nanoplatform was based on a particular protease substratum assessment
of Pseudomonas aeruginosa proteolytic activity. The substrate was covalently attached to
MNPs on its N-terminus and connected to an Au sensor surface on its C-terminus. Gener-
ally, the Au nanosensor appears black to the naked eye due to coating with MNPs but at
proteolysis, the peptide-MNP moieties are cleaved and absorbed by an external magnet.
Thereafter, the golden color of the sensor surface becomes observable by the naked eye.
In vitro, the biosensor identified the presence of Pseudomonas aeruginosa with 102 colony-
forming units (cfu)/mL in less than 1 min while was capable of successfully detecting
Pseudomonas aeruginosa in samples from patients.
In resource-limited environments, the point-of-care identification of pathogens in biolog-
ical samples needs to be rapid, simple, cost-effective, compact, precise. Michael et al. [101]
generated a custom-made fidget spinner based on Au NPs that rapidly concentrate the
pathogens more than 100 times in 1 mL samples of undiluted urine for on-device colori-
metric identification of bacterial loads and pathogen detection. The system allowed for the
on-site, naked-eye identification of infection in urine samples from 39 patients suspected
of having UTIs within 50 min. The authors also demonstrated that the system could be
applied in 30 clinical samples of UTIs to conduct an antimicrobial susceptibility experiment
within 120 min for the antimicrobial drugs ciprofloxacin and cefazolin. This fidget spinner
may be used as an affordable portable system for the rapid concentration and identification
of pathogens in urine samples in low-resource settings.
A mobile origami sensor was developed by Adrover-Jaume et al. [102] capable of
detecting UTIs caused by Escherichia coli in less than 7 min. A single piece of paper
containing antibody-decorated Au NPs was made from an origami nanosensor. If a sample
of urine would contain Escherichia coli, the biosensors would produce colored spots on the
paper strip that may be quantified by a mobile app by pixel measurements in real-time.
The examinations were highly precise and did not crossreact with other uropathogens. In
addition, when tested using a panel of 57 urine samples from patients, the biosensors only
yielded one false-negative test, demonstrating their strong specificity and sensitivity. This
result, along with a quick assessment time and smartphone-based identification, makes
such biosensors a useful system to accurately identify UTIs.
Due to their excellent efficiency, low cost, and capacity to identify a broad range of
target molecules such as nucleic acids and protein biomarkers, electrochemical nanosensors
are well adapted for urinary diagnostics [103,104]. For a rapid measurement of the UTI
lactoferrin biomarker, Pan et al. [105] created an electrochemical immunosensor (nanoarray
of self-assembled monolayer alkanethiolate) from infected serum samples. Lactoferrin is a
biomarker of pyuria (white blood cell involvement in urine), an essential UTI symptom [106].
The limit of detection (LOD) of the study was 145 pg/mL and the simultaneous identification
of bacterial nucleic acid (16S rRNA) and of host immune response-associated protein
(lactoferrin) on a single sensor array showed multichannel detection of uropathogens
and lactoferrin. These findings provided the first interconnected nanoplatform for both
quantitative pathogen detection and host immune response assessment.
There are some drawbacks to the commercially available colorimetric urine dipstic for
early UTI detection. Identification and quantification of urinary leukocyte esterase (LE)
remain unclear for the prediction of UTIs [107]. To solve this problem, Ho et al. [108] pro-
posed a paper-based analytical device (PAD) to detect LE (LE-PAD) as a proof-of-concept
UTI quantitative test. The LE-PAD consists of a mixed coating of 3-(N-tosyl-L-alaninyloxy)-
5-phenylpyrrole (PE) and 1-diazo-2-naphthol-4-sulfonic acid (DAS) accumulated on an Ag
film or Ag NPs. The analysis indicated that the LE amount calculated by LE-PADs was
descriptive of UTI diagnosis, with an area of 0.875 (95% confidence interval, 0.704–1.000)
under the receiver operating characteristic curve. Using an acceptable cut-off value, the LE-
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UTI PAD’s diagnosis specificity and sensitivity were 87.5% and 92.3%, respectively, while
urine dipstic LE positivities were 62.5% and 76.9%, respectively. The LE-PAD displayed
positive and negative probability ratios of 11.38 and 0.14 for UTI diagnosis, indicating that
the new LE-PAD may be a valid method.
Novel biosensors have been recently developed based on the unusual plasmonic energy
exchange of nanometallic crossed surface-relief gratings (CSRGs). CSRG-based nanosensing,
nevertheless, has been restricted to spectroscopic methods and has not exploited its capacity
for incorporation with pervasive electronic devices [109]. Nair et al. [109] introduced a
novel nanosensor using surface plasmon resonance imaging (SPRi) allowed by CSRGs. The
imaging system used two-dimensional nanoplasmonic gratings to facilitate a specific trans-
fer of plasmonic energy between metallic nanomaterials. Finite-difference time-domain
(FDTD) simulations confirmed that, due to plasmon resonance at the metal–dielectric inter-
face, CSRG-enabled SPRi was accompanied by an electric field intensity enhancement of
about 30 times. The rapid (<35 min) and label-free detection of UPEC in phosphate-buffered
saline (PBS) and in human urine samples from 103 to 109 cfu/mL showed the performance
of the system for biomedical applications. The platform’s LOD was around 100 cfu/mL,
i.e., three orders of magnitude below the clinical LOD for UTI detection. The sensing ability
of the platform was demonstrated experimentally by the diagnosis of differences in the
bulk refractive index (RI), with a sensitivity of 382.2 nm/RI units (RIU) and a resolution of
10−6 RIU. Brayner et al. reported studies of cellular internalization of ZnO nanoparticles
on Escherichia coli bacteria [110].
Table 1 summarizes the most commonly used NP-based sensors for the diagnosis
of UTIs.




detection of Proteus mirabilis PRM1,
Escherichia coli CFT 073, and
Pseudomonas aeruginosa PAO1 uropathogens
[99]
nanopaper-based systems detection of LE (LE-PAD) as a proof-of-conceptfor UTI quantitative testing [108]
MNPs identification of Pseudomonas aeruginosa in vivo [111]
Abbreviations: SERS, surface-enhanced Raman scattering; MNPs, magnetic nanoparticles; LE, leukocyte esterase;
LE-PAD, leukocyte esterase-paper-based analytical device; UTI, urinary tract infection.
4. Nanomaterials for the Treatment of UTIs
Compared with conventional antimicrobials, NP-based antimicrobials are easy to
fabricate and display prolonged stability, sustained drug release, and higher therapeutic
efficacy. NPs that possess antimicrobial properties themselves or increase the therapeutic
efficiency of antibiotics are referred nanoantibiotics [112]. Nanoantibiotics kill pathogens
through multiple mechanisms including via formation of ROS, interference with energy
transduction pathway, inhibition of DNA synthesis, and degradation of the microbial
cell wall [113]. Although conventional antimicrobial therapies are effective in inhibiting
bacteria, these therapies are ineffective to act against dormant intracellular pathogens due
to poor penetration. As a consequence, several pathogens take advantage of this limitation
and cause UTI recurrence. Nanoantibiotics possess the capabilities to target the intracellular
reservoirs of the pathogens and thus to limit the recurrence of the diseases. Due to the
promising advantages of MPs, several antimicrobial-laden NPs such as metals and metal
oxides, dendrimers, surfactant-based NPs, and carbon-based nanomaterials have been
employed for UTI therapy [114].
4.1. Metallic NPs with Antimicrobial Activity
Due to their small size, high surface area, shape, and surface charge, metallic NPs are
the most suitable nanocarriers for higher cellular uptake of antimicrobials. The conjuga-
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tion of certain functional groups on their surface increases the cellular interaction of the
NPs [115]. Owing to their small size, metallic NPs also exhibit higher cellular penetration
than free antimicrobials and are easily absorbed from the blood circulation to the target site.
Due to these unique features, several groups employed metallic NPs to achieve efficient
delivery of antimicrobials against UTIs [116]. Among the several kinds of metallic NPs,
the mechanism of some of the new NPs is still not understood [117–122]. The mechanisms
employed by metallic NPs to exert antimicrobial activities are presented in Figure 2. Exam-
ples of metallic-based NPs with antimicrobial properties include iron-, Ag-, Au-, Ag oxide-,
titanium dioxide-, aluminum oxide-, copper oxide-, and gallium-based NPs [123,124].
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4.2. Silver-Based NPs
When the particle size of Ag is reduced to the nanorange, it exhibits antibacterial
activities against Staphylococcus aureus and Escherichia coli. Ag NPs exhibit antimicrobial
properties by affecting the division and respiratory system of microorganisms. Even though
the long-term exposure to soluble Ag causes adverse effects on the intestinal tract and
kidneys, Ag NPs exhibit negligible effects on human health.
Synthesis of silver-based and other metallic NPs can be achieved through physical,
chemical, and biological methods. However, p ysical and chemical methods are associated
with a number of rawbacks including the production of hazardous wastes, the diffi-
culty in scale-up productio , and the instabili y in ggregation while requiring expe sive
organometallic pr cursors for the synthesis of NPs. On other hand, biological methods
are regarded as safe procedures, using bacteria as potential biofactories for the synthesis
of metallic NPs, making them more “eco-friendly” systems than physical and chemical
methods. To exploit the advantages of eco-friendly approach, Divya et al. [125] synthesized
eco-friendly Ag NPs with antimicrobial properties against several UTI pathogens and
coated them on catheters that overall displayed antibiofilm and antimicrobial properties.
Saleh et al. [126] formulated and investigated the mechanisms of antimicrobial action
of two different types of metallic NPs, i.e., Ag-based and titanium dioxide-based NPs,
against Proteus vulgaris and Proteus mirabilis, reporting that both kinds of NPs inhibited
the microbial species via downregulation of fliL gene expression directly associated with
blockade of the movement of the Proteus species. Similarly, Das et al. [127] created Ag NPs
loaded with the extract of Oxalis corniculata and observed that compared with pure extract,
extract-based Ag NPs exhibited significantly higher antimicrobial activities against both
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Gram-positive and Gram-negative bacterial strains, the leading cause of UTIs. In addition,
the authors also reported that the formulations allowed for significantly higher kidney
stone dissolution, an effect further increased in the presence of Ag NPs.
Pseudomonas aeruginosa is considered a critical agent for the formation of antibiotic-
resilient biofilms, reducing the therapeutic efficacy of antimicrobials. While Ag NPs
are seen as an efficient choice to overcome such events due to their innate bactericidal
potential, they may be toxic when used at high concentrations. To tackle such an issue,
Bhargava et al. [128] functionalized the surface of the Ag NPs with fucose to increase
their interaction with the lectin B component of the bacterial cell wall. The results of the
study demonstrated a superior bactericidal and antibiofilm activity of the functionalized
NPs. The key findings of the fluorescence study and confocal laser scanning microscopy
revealed that the bactericidal activity was achieved due to the generation of higher ROS
and oxidative stress-induced membrane damage. In addition, the functionalized NPs also
exhibited a higher antibiofilm-forming potential through the downregulation of several
virulence genes.
MDR has become a worldwide issue, showing the urgent need to develop strategies
to overcome this critical problem. In this regard, Lopez-Carrizales et al. [129] developed
Ag-based NPs to co-deliver amikacin and ampicillin versus single antimicrobial treatment.
When ampicillin was administered in combination with Ag NPs against twelve micro-
bial strains of UTIs, the system displayed synergistic effects against one strain, partial
synergistic effects against seven strains, and additive impact against four strains. When
amikacin was used in combination with Ag NPs, this second system displayed synergistic
impact against three strains, partial synergistic impact against eight strains, and exhibited
additive effect against another single strain. The cytotoxic effects of both combination
approaches at the given concentrations were insignificant relative to the use of single drugs.
Based on these results, the authors concluded that MDR may be overcome through a
synergistic combined approach. Similarly, El-Batal et al. [130] investigated the potential
of Ag- and boron-based NPs against MDR microbial strains. The NPs were formulated
through γ-radiation-induced synthesis of Ag-boron NPs using an eco-friendly approach
with polyvinylpyrrolidone as the stabilizing agent. These NPs exhibited zones of inhibition
of 20 mm, 18 mm, and 16 mm and biofilm inhibition of 87%, 85.3%, and 69.4% against
Candida albicans, Escherichia coli, and Staphylococcus aureus, respectively. Mishra et al. [131]
formulated Ag NPs loaded with timber-yielding plant extract, having a particle size less
than 100 nm. The antibacterial efficacy of the prepared formulation was evaluated against
11 MDR bacterial strains responsible for UTIs. Compared with the standard gentamicin
(30 µg/mL), the prepared nanoformulation (15 µg/mL) significantly reduced the zone of
inhibition from 30 to 13 mm. The toxicity of the prepared formulation was also investigated
in cultured lymphocytes obtained from umbilical cord blood, showing cell death below
25%, supporting the concept of safely using these systems against MDR UTIs.
Rodríguez-Serrano et al. [132] produced Ag NPs through an eco-friendly approach
using soil fungal to treat UPEC UTIs. Escherichia coli tend to form a biofilm which reduces
the penetration and the efficacy of conventional antibiotics. The biogenic Ag NPs were
formulated using metabolites excreted from the fungal strains. The prepared formulations
had a minimum inhibitory concentration (MIC) of 7.5 mg/mL with a 97% reduction in
biofilm formation and an 80% destruction of the matured biofilm, while the control group
had a MIC value of 25 mg/mL.
Foley catheters are essential in the healthcare unit and pathogens tend to form biofilms
on the surface of catheters, leading toward UTIs. To prevent this problem, researchers
functionalized the surface of catheters using a combination of Ag NPs and antibiotics [133].
NPs were produced in a size range of 42–75 nm for investigation in vivo in mice. The
combination of amikacin, nitrofurantoin, and Ag NPs exhibited synergistic activity. Mice
treated with the combination approach did not show any kind of colonization until day 14.
After 2 years, the catheters treated with antibiotics exhibited a 25% reduction in bacterial
adhesion while the group treated with Ag NPs along with antibiotics displayed a 90%
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decline in bacteria adhesion. Shafreen et al. [134] also formulated Ag NPs using fresh
water diatom, showing inhibition against Escherichia coli at a concentration of 300 ng/mL
and decreasing biofilm formation. Confocal laser microscopy further showed that the
architecture of the biofilm was also significantly decreased. Valsalam et al. [135] prepared
Ag NPs through an eco-friendly approach using leaf extract from Tropaeolum majus. Both
Ag NPs and plant extract inhibited Pseudomonas aeroginosa at a concentration of 6.25 µg/mL
relative to other microbial strains and exhibited antifungal and anticancer activities that
may be used for the treatment of other infectious diseases.
4.3. Copper NPs
Due to the redox-active properties of copper, several groups employed copper-based
NPs for their activity against UTIs. In this regard, Al-Enizi et al. [136] formulated a
copper NP-based hydrogel matrix, with a particle size distribution of 7-12 nm. The an-
timicrobial and cytotoxic activities of the formulation were evaluated in UTI microbes
(Escherichia coli, Klebsiella pnemoniae, Pseudomonas aeruginosa, Proteus vulgaris, Staphylococ-
cus aureus, Proteus mirabilis) and HeLa cell lines. Compared with a simple gel matrix, the
copper NP-based hydrogel matrix exhibited a significantly higher zone of inhibition against
UTI pathogens while cytotoxicity studies revealed the suitability of the prepared carrier
system for biomedical applications. Shalom et al. [137] fabricated zinc-doped copper oxide
NPs for the treatment of catheter-linked UTIs. The NPs were deposited on the surface of the
catheter through the sonochemical technique. The surface-coated catheter exhibited higher
antibiofilm property, biocompatibility, reduced cytokines secretion, lower cytotoxicity, and
absence of irritation in rabbits. The coated catheters did not produce UTIs even 7 days after
application while the uncoated catheters exhibited UTIs within 4 days.
4.4. Silicone Dioxide-Based NPs
Muslim et al. [138] generated tannase-conjugated silicone dioxide-based NPs through
laser ablation technique, noting higher therapeutic effectiveness and significance levels
against all UTI pathogenic strains compared with control groups, as an effective approach
against UTIs.
4.5. Zinc Oxide NPs
Zinc oxide NPs exhibit cell internalization and bactericidal effects against several
microbial strains involved in UTIs. Due to these properties, several researchers used zinc
oxide (ZnO)-based NPs for therapy against UTIs.
In this context, Santhoshkumar et al. [139] fabricated Passiflora caerulea leaf extract-
based ZnO NPs. Compared with simple leaf extract, the leaf extract-laden ZnO NPs
exhibited a significantly higher zone of inhibition in the pathogenic microbes extracted
from patients’ urine containing UTIs. Abd Elkodous et al. [140] examined the antimicrobial
and antibiofilm properties of ZnO NPs against MDR bacterial strains involved in UTIs. The
NPs exhibited a particle size of 69 nm, a surface area of 10.66 m2/g, and porosity of 13.16%
and displayed antimicrobial and antibiofilm activities against all the pathogenic UTI strains.
Tiwari et al. [141] investigated the potential of ZnO NPs against carbapenem-resistant
microbial strains. The NPs were 30 nm in size and displayed significant antibacterial
activities against the resistant strains. The authors also investigated the mechanisms of
microbial inhibition and found that ZnO NPs promoted the production of ROS which, in
turn, increased the peroxidation of the bacterial membrane lipids and the leakage of DNA,
reducing sugars, proteins, and ultimately leading to a reduction of the cell viability. These
results demonstrated that ZnO NPs have the potential to be effectively used against the
resistant strains of UTIs. Similarly, El-Rab et al. [142] evaluated the inhibition potential and
mechanism of ZnO NPs against the MDR strains of Escherichia coli and Escherichia hermannii.
The NPs inhibited Escherichia coli at a concentration of 10 µg/mL and Escherichia hermannii
at 40 µg/mL. The MIC values reported in the study were also significantly lower than in
earlier evaluations. The authors also evaluated the mechanisms of inhibition of the microbes
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and an SEM analysis showed the distortion and blebbing of the microbial membrane, with
an elongation of the cell membrane and a discharge of cellular contents. In another study,
Hosseini et al. [143] tested the impact of ZnO NPs on the initiation, adhesion, agglutinin
sequence, and gene expression in biofilm formation. The NPs displayed size of 20–40 nm
and MIC in the range of 0.02–18.1 µg/mL. The authors observed that at this concentration,
the NPs induced an initial inhibition and then tremendous reduction of the expression of
genes responsible for biofilm formation. Such NPs may thus be effectively used to prevent
biofilm formation with increased efficacy against microbes. Hosseini et al. [144] evaluated
the impact of ZnO NPs on the adhesion of Candida albicans on surface catheter and biofilm
formation. Among the several bacterial species tested, Candida albicans fluconazole-resistant
strains exhibited higher adherence to the surface of catheters. The surface-adhered catheters
were then treated with ZnO NPs, leading to a reduced biofilm mass. This study illustrated
that ZnO NPs may be additionally used for the treatment of catheter-allied UTIs.
4.6. Selenium-Based NPs
El-Sayyad et al. [145] formulated gentamicin-laden selenium NPs to compare and in-
crease the antibiofilm and antimicrobial activities of conventional gentamicin formulations
against MDR microbial strains. The NPs had a particle size distribution in the range of
22–33 nm and displayed antimicrobial properties against all MDR strains of UTIs. The for-
mulation also showed enhanced antibiofilm properties of 88% against Staphylococcus aureus,
87% against Pseudomonas aeruginosa, and 85% against Escherichia coli.
4.7. Sulfur-Based NPs
The majority of microbial strains exhibit resistance to trimethoprim and amoxicillin.
To overcome such resistance, Paralikar et al. [146] prepared sulfur NPs (SNPs) loaded with
trimethoprim and amoxicillin with a size in the range of 20–86 nm and with lower poly-
dispersity index. SNPs combined with trimethoprim and amoxicillin exerted a synergistic
effect and higher zone of inhibition against the resistant microbial strains compared with
unloaded SNPs.
4.8. Polymeric NPs
Due to their high stability, encapsulation efficiency, and ability to modify the surface
properties, polymeric NPs are extensively utilized as a nanocarrier for the efficient loading
of antimicrobial agents. To exploit such properties, Park et al. [147] generated a pH-
sensitive and redox-responsive polymer-based nanocarrier for the efficient delivery of
amphotericin B. The authors further attached the functional moieties with an antifungal
histatin 5 peptide allowing for targeted delivery and displaying antifungal properties
against Candida albicans. The mechanisms of targeted delivery are presented in Figure 3.
Compared with free amphotericin B, the nanoformulation exhibited higher therapeutic
efficacy and targeted delivery to the pathogenic microbe-laden cells at lower doses while
reducing the cytotoxicity to healthy cells.
Crystalline deposition and formation of biofilms are the common reasons for the
failure of prolonged urinary catheter-based therapy against UTIs. Bacteria colonize the
surface of the catheter, block it, ultimately leading to serious UTIs. To address this problem,
Dayyoub et al. [148] developed a new strategy to counteract the adhesion of pathogens to
the catheter surface based on a nanoformulation consisting of norfloxacin, Ag NPs, and
polylactic-co-glycolic acid (PLGA)-based polymers which underwent degradation in the
aqueous environment and produced alkali products through the hydrolysis of the urea. The
authors examined the adhesion of the NPs embedded with tetraether lipids on silicone and
polyurethane sheets. Compared with commercial formulations, the current NPs exhibited
significantly higher anti-adhesion and antimicrobial properties. An in vivo encrustation
model revealed that the lipid coating reduced adhesion for 2 weeks, supporting the concept
of using such a system as an efficient coating for urinary catheters.
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Figure 3. Conjugation of histatin 5 and amphotericin B with NPs. (A) conjugation of histatin 5 with
chitosan and conjugation of a redox linker with amphotericin B (a), self-assembly of NPs through
disulfide bonds between polymeric chains and formation of micelles through hydrophobic interaction
of amphotericin B (b), pH-dependent activation of the targeting ligand, i.e., histatin 5 (c), release
of amphotericin B through a reduction mechanism within the fungal cell (d). (B) Targeted uptake
and intraendosomal release of amphotericin B and synergistic action of histatin B against fungal
destruction. Reproduced from [147], with permission from Elsevier, 2021.
Intravesical therapy used for therapy against bladder cancer may be further adapted
for the treatment of UTIs, although certain issues associated with this technique still need
attention such as a short dwelling and washout period. In this regard, Brauner et al. [149]
formulated two types of PLGA 2300- and PLGA 503H-based NP surface tailored with
wheat germ agglutinin. Both types of NPs significantly enhanced the adhesion of the NPs
to human uroepithelial cells while the loading of trimethoprim did not alter the adhesion
potential of the NPs. The highest adhesion was observed in sodium bicarbonate buffer at
pH 5. The dwelling time was in the range of 15–30 min, and after 15 min less than 50% of
the NPs were bound to the surface while more than 70% were bound after 30 min, without
further increment beyond this time point. Such surface-functionalized NPs may thus be
used as a promising approach for therapy against UTIs.
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Amphotericin B is a commonly used antibiotic for UTIs, yet it may lead to hemolytic
anemia and nephrotoxicity. In an attempt to reduce such hurdles, Ludwig et al. [150]
created PLGA-based NPs decorated with chitosan for the efficient loading of amphotericin
B. The NPs exhibited a size of 460 nm and encapsulation efficiency of 46%. Compared with
free drugs, amphotericin B-loaded NPs exhibited lower MIC, a higher zone of inhibition,
and reduced adverse effects.
Sharma et al. [151] developed chitosan-based zingerone NPs against Pseudomonas aerug-
inosa to treat catheter-induced UTIs. Due to the antimicrobial properties of chitosan, these
NPs exhibited a synergistic effect against the pathogens without toxicity in kidney cell
lines. Findings in vivo revealed that chitosan-based NPs decreased the bacterial cell count
in the bladder and renal tissues and ex vivo studies evidence the intracellular killing of
the pathogen and higher uptake by phagocytes with an important reduction of the level of
several inflammatory mediators.
4.9. Hybrid NPs (Polymeric/Metallic NPs)
One of the reasons for the occurrence of UTIs is the presence of the ureteral stent and
the pain associated with extraction. In this regard, Gao et al. [152] prepared an extraction
of free, biodegradable, and antibacterial stent having a continuous renewable surface and
antibiofilm properties through the construction of poly(amide-amine)-capped Ag shell and
Au core nanoparticle (Ag@Au NP)-embedded fiber membrane-structured poly(glycolic
acid) (PGA)/PGLA NPs. The stent exhibited a rapid killing kinetics of Staphylococcus aureus
and Escherichia coli within 10 and 5 min, respectively, along with an inhibition rate of up to
99%. The gradual degradation of PGA and PLGA self-cleaned the stent and also displayed
antibacterial properties through constant exfoliation of the surface of the stent. The stent
also exhibited biocompatibility, lower cytotoxicity, and bactericidal activity. In vivo studies
in pigs revealed that the stent had significant antibiofilm properties and decreased the
levels of necrotic and inflammatory cells, as a promising and extraction-free approach to
treat UTIs.
Ashmore et al. [111] compared the antimicrobial properties of polymer-coated Ag NPs,
i.e., 10% Ag (Ag 10% + polymer) and 99% Ag (Ag-polyvinylpyrrolidone—AgPVP), versus
uncoated NPs. NPs coated with polymer exhibited higher potency against Escherichia coli
compared with the uncoated NPs, with bacterial growth inhibited within 8 h at a con-
centration of 0.156 mg/mL while uncoated NPs were effective at 0.312 mg/mL. An SEM
analysis revealed that the formulations destroyed the cell membrane, leading to bacterial
cell rupture and expulsion of the cellular content.
Acinetobacter baumannii is one of the several microbes with MDR against UTIs, with all
conventional antibiotics being largely ineffective to prevent their occurrence. Plant-based
extracts have currently gained much attention to avoid the problem of MDR. With this
in mind, Tiwari et al. [153] investigated plant extracts from various species to explore
their antimicrobial activities against MDR pathogenic microbes. Among them, a complete
extract or primary and secondary metabolites from Phyllanthus emblica showed the highest
inhibition potential for carbapenem-resistant Acinetobacter baumannii via the production of
ROS, carbonylation of proteins, and membrane damage. To further confirm the antimicro-
bial properties of the secondary metabolites, gallate (the major secondary metabolite of
the plant)-laden PVP-capped hybrid Ag NPs (G-PVP-Ag NPs) were formulated and had
significant antimicrobial activity also via ROS production.
4.10. Surfactant-Based NPs
Pseudomonas aeruginosa is the microorganism that causes hospital-acquired UTIs. This
organism can grow in a free form as well as on biofilm colonies attached to a surface. When
the species grows in the biofilms, the presence of biofilms limits the efficacy of conventional
formulations, leading to its resistance. To overcome this issue, Lopes et al. [154] evaluated
the anti-biofilm potential of a glycerol monolaurate (GML) nanoformulation with an
average diameter of 190 nm. Compared with free GML, GML nanocapsules reduced the
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MIC from 62.5 to 15.62 µg/mL as well as the biofilm mass, polysaccharides, proteins, and
the presence of Pseudomonas aeruginosa on the biofilms.
4.11. Carbon-Based Nanomaterials
Carbon-based nanomaterials have been widely employed due to their unique op-
tical and tunable surface properties, low systemic toxicities, cost-effectiveness, and an-
timicrobial activities. Due to these features, Lu et al. [155] took advantage of carbon-
based materials against UTIs, such as graphene, carbon nanotubes, and nanodiamonds.
Dybowska-Sarapuk et al. [156] also formulated carbon-based nanolayers using graphene
decorated with Ag NPs against the formation of Staphylococcus epidermidis-induced biofilm
on the surface of the Foley catheter. Such graphene-nanoAg nanolayers were capable of
preventing biofilm formation on the surface of the catheter, as a strong tool against the
complications associated with UTIs. Rouhani et al. [157] functionalized amoxicillin-based
nanodiamonds with polyethyleneimine (PEI) and conjugation with ferromagnetic material
(Fe3O4) to achieve active targeted delivery. The nanodiamonds were capable to release the
drug in the target sites to overcome the problem of dose-related resistance associated with
a free drug approach against UTIs.
It is estimated that there are 25–45% chances of relapse in women suffering from UTIs
mostly due to Escherichia coli infection, as a result of the internalization of the pathogen
in the urinary bladder and since antibiotics fail to reach the target site. To tackle this
problem, Iyer et al. [158] prepared two types of nanodiamonds with sizes of 6 and 25 nm to
kill intracellular and extracellular pathogens. Nanodiamonds with a size of 6 nm had a
more potent internalization capability than 25 nm-sized systems, using a mechanism based
on actin-dependent endocytosis, and better reduced bacterial infiltration, improving the
killing kinetics of the Escherichia coli.
4.12. Dendrimer-Based Nanomaterials
Dendrimers are artificial macromolecules with several functional groups and an
intact molecular structure, playing an increasing role in drug delivery via the fabrication
of nanoscale particles. Sehad et al. [159] created surface-functionalized dendrimers by
attaching mannose sugar on the surface of the dendrimers through copper-catalyzed cyclo-
addition click reaction. The mannosylated dendrimers were constructed to examine the
impact of mannosylation upon the binding capacity of dendrimers on the bacterial cell
surface. The dendrimers had the ability to bind with FimH type-1 lectins present at the
tip of bacterial fimbriae, showing high potency, bioadhesion, and antibiofilm properties
against Escherichia coli. Zhu et al. [160] generated mannoside-decorated dendrimers to
increase the formation of a protecting coating to avoid the adhesion of pathogenic microbes
at the surface of silicone catheters. The authors reported that 95% of nonpathogenic
microbes were retained on the catheters while all MDR pathogenic strains were excluded
from colonization at their surface. The most commonly used nanoparticle-based delivery
approaches against several species of UTIs are presented in Table 2.
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Table 2. Most commonly used NP-based delivery approaches for therapy against UTIs.




MIC of 7.5 mg/mL, 97% reduction of




Escherichia coli, Klebsiella pnemoniae,
Pseudomonas aeruginosa, Proteus vulgaris,
Staphylococcus aureus, Proteus mirabilis
high zone of inhibition against UTI
pathogens, low cytotoxicity of the NPs [161]
ZnO Escherichia coli, Escherichia hermannii
anti-bacterial effects at 10 and 40 µg/mL




(chitosan-based NPs) Candida albicans
high therapeutic efficacy and targeting
of pathogenic microbe-laden cells,
low cytotoxicity
[163]
hybrid NPs Escherichia coli high potency (inhibition of bacterialgrowth within 8 h at 0.156 mg/mL) [111]
carbon-based NPs Staphylococcus epidermidis
prevention of biofilm formation on
Foley catheter by graphene-nano
Ag nanolayers
[164]
Abbreviations: NPs, nanoparticles; Ag, silver; ZnO, zinc oxide; MIC, minimum inhibitory concentration; UTI, urinary tract infection.
5. Conclusions, Challenges, and Perspectives
Compared with conventional therapies, NP-mediated delivery of antimicrobials dis-
plays higher therapeutic efficacy by minimizing off-target delivery and by managing MDR.
The issue of biofilm formation, an additional barrier that impairs the therapeutic efficacy
of antimicrobials, may also be addressed using the nanotechnology procedure, especially
when using metallic NPs that possess an intrinsic antibiofilm formation potential. With
the emerging role of nanotechnology in drug delivery and diagnostics, this approach may
further overcome the limitations of conventional therapies in clinical trials, making it the
most appealing strategy for the diagnosis, treatment, and prevention of UTIs. In order to
minimize the seriousness of these infections, the early diagnosis of UTIs will play a major
role in their rapid eradication, and any delay in effective UTI detection may result in the
development of intracellular reservoirs particularly difficult to eliminate. The integration
of nanomaterials with the currently available diagnosis methods will be a strong option for
the early-stage identification of UTIs and may solve the major constraints in evaluation
and therapy, including infection recurrence. Although NPs have the potential to treat and
diagnose UTIs, there are still several challenges that need to be addressed prior to their
successful translation in the clinics including the investigation of the interaction between
NPs and cells, tissues, and organs, the identification of the most appropriate routes of
administration, and most importantly the evaluation of toxic responses to long-term expo-
sure to NPs. Despite several advancements regarding the value of NPs in the diagnosis
and treatment of UTIs, it will be important to examine the pathways through which NPs
exert their therapeutic efficacy. There is also limited information on the metabolism and
clearance of NPs and on the nature of their targets. The specific combination of NPs
and antimicrobials may reduce the emergence of multidrug resistance of bacteria to drug
sensitivity and translation to clinical practice will require a thorough investigation of the
pharmacokinetic and pharmacodynamic profiles of these NPs. Finally, for innovative
research, the limits of pathogen detection and the time of the proposed analysis will have
to be significantly improved.
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14. Behzadi, P.; Urbán, E.; Matuz, M.; Benkő, R.; Gajdács, M. The role of gram-negative bacteria in urinary tract infections: Current
concepts and therapeutic options. Adv. Exp. Med. Biol. 2020. [CrossRef]
15. Gajdács, M.; Ábrók, M.; Lázár, A.; Burián, K. Increasing relevance of Gram-positive cocci in urinary tract infections: A 10-year
analysis of their prevalence and resistance trends. Sci. Rep. 2020, 10, 1–11. [CrossRef]
16. Bassetti, M.; Echols, R.; Matsunaga, Y.; Ariyasu, M.; Doi, Y.; Ferrer, R.; Lodise, T.P.; Naas, T.; Niki, Y.; Paterson, D.L. Efficacy
and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-
negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet
Infect. Dis. 2021, 21, 226–240. [CrossRef]
17. Hozzari, A.; Behzadi, P.; Khiabani, P.K.; Sholeh, M.; Sabokroo, N. Clinical cases, drug resistance, and virulence genes profiling in
uropathogenic Escherichia coli. J. Appl. Genet. 2020, 61, 265–273. [CrossRef] [PubMed]
18. Behzadi, P. Classical chaperone-usher (CU) adhesive fimbriome: Uropathogenic Escherichia coli (UPEC) and urinary tract
infections (UTIs). Folia Microbiol. 2020, 65, 45–65. [CrossRef]
19. Wasfi, R.; Hamed, S.M.; Abd Allah, M.A.W.; Ismail, L. Proteus mirabilis biofilm: Development and therapeutic strategies. Front.
Cell. Infect. Microbiol. 2020, 10, 414. [CrossRef] [PubMed]
20. Vagios, S.; Hesham, H.; Mitchell, C. Understanding the potential of lactobacilli in recurrent UTI prevention. Microb. Pathog. 2020,
148, 104544. [CrossRef]
21. Heidemann, J.; Schmitz, B.; Kostev, K. Association between antiseizure medication use and risk of urinary tract infection: A
case–control study. Epilepsy Behav. 2020, 115, 107502. [CrossRef] [PubMed]
Nanomaterials 2021, 11, 546 16 of 21
22. Zhong, Z.-X.; Cui, Z.-H.; Li, X.-J.; Tang, T.; Zheng, Z.-J.; Ni, W.-N.; Fang, L.-X.; Zhou, Y.-F.; Yu, Y.; Liu, Y.-H. Nitrofurantoin
combined with amikacin: A promising alternative strategy for combating MDR uropathogenic Escherichia coli. Front. Cell. Infect.
Microbiol. 2020, 10, 811. [CrossRef] [PubMed]
23. Loubet, P.; Ranfaing, J.; Dinh, A.; Dunyach-Remy, C.; Bernard, L.; Bruyère, F.; Lavigne, J.-P.; Sotto, A. Alternative therapeutic
options to antibiotics for the treatment of urinary tract infections. Front. Microbiol. 2020, 11, 1509. [CrossRef] [PubMed]
24. Magistro, G.; Stief, C.G. Vaccine development for urinary tract infections: Where do we stand? Eur. Urol. Focus 2019, 5, 39–41.
[CrossRef] [PubMed]
25. AL-Khikani, F.H.O.; Abadi, R.M.; Ayit, A.S. Emerging carbapenemase Klebsiella oxytoca with multidrug resistance implicated in
urinary tract infection. Biomed. Biotechnol. Res. J. (BBRJ) 2020, 4, 148.
26. Horváth, J.; Wullt, B.; Naber, K.G.; Köves, B. Biomarkers in urinary tract infections—Which ones are suitable for diagnostics and
follow-up? GMS Infect. Dis. 2020. [CrossRef]
27. Martínez-Figueroa, C.; Cortés-Sarabia, K.; del Carmen Alarcón-Romero, L.; Catalán-Nájera, H.G.; Martínez-Alarcón, M.; Vences-
Velázquez, A. Observation of intracellular bacterial communities in urinary sediment using brightfield microscopy; a case report.
BMC Urol. 2020, 20, 89. [CrossRef]
28. Dospinescu, V.-M.; Tiele, A.; Covington, J.A. Sniffing out urinary tract infection—Diagnosis based on volatile organic compounds
and smell profile. Biosensors 2020, 10, 83. [CrossRef]
29. Dixon, M.; Stefil, M.; McDonald, M.; Bjerklund-Johansen, T.E.; Naber, K.; Wagenlehner, F.; Mouraviev, V. Metagenomics in
diagnosis and improved targeted treatment of UTI. World J. Urol. 2020, 38, 35–43. [CrossRef]
30. Fritzenwanker, M.; Imirzalioglu, C.; Chakraborty, T.; Wagenlehner, F.M. Modern diagnostic methods for urinary tract infections.
Expert Rev. Anti-Infect. Ther. 2016, 14, 1047–1063. [CrossRef]
31. Thapaliya, J.; Khadka, P.; Thapa, S.; Gongal, C. Enhanced quantitative urine culture technique, a slight modification, in detecting
under-diagnosed pediatric urinary tract infection. BMC Res. Notes 2020, 13, 5. [CrossRef]
32. Bannov, A.G.; Popov, M.V.; Kurmashov, P.B. Thermal analysis of carbon nanomaterials: Advantages and problems of interpreta-
tion. J. Therm. Anal. Calorim. 2020, 142, 349–370. [CrossRef]
33. Kumar, M.S.; Das, A.P. Emerging nanotechnology based strategies for diagnosis and therapeutics of urinary tract infections: A
review. Adv. Colloid Interface Sci. 2017, 249, 53–65. [CrossRef] [PubMed]
34. Bartelds, R.; Nematollahi, M.H.; Pols, T.; Stuart, M.C.; Pardakhty, A.; Asadikaram, G.; Poolman, B. Niosomes, an alternative for
liposomal delivery. PLoS ONE 2018, 13, e0194179. [CrossRef] [PubMed]
35. Nematollahi, M.H.; Pardakhty, A.; Torkzadeh-Mahanai, M.; Mehrabani, M.; Asadikaram, G. Changes in physical and chemical
properties of niosome membrane induced by cholesterol: A promising approach for niosome bilayer intervention. RSC Adv. 2017,
7, 49463–49472. [CrossRef]
36. Goudarzi, K.A.; Nematollahi, M.H.; Khanbabaei, H.; Nave, H.H.; Mirzaei, H.R.; Pourghadamyari, H.; Sahebkar, A. Targeted
delivery of CRISPR/Cas13 as a promising therapeutic approach to treat SARS-CoV-2. Curr. Pharm. Biotechnol. 2020. [CrossRef]
37. Dakal, T.C.; Kumar, A.; Majumdar, R.S.; Yadav, V. Mechanistic basis of antimicrobial actions of silver nanoparticles. Front.
Microbiol. 2016, 7, 1831. [CrossRef] [PubMed]
38. Kumar, H.; Bhardwaj, K.; Dhanjal, D.S.; Nepovimova, E.; S, en, F.; Regassa, H.; Singh, R.; Verma, R.; Kumar, V.; Kumar, D. Fruit
extract mediated green synthesis of metallic nanoparticles: A new avenue in pomology applications. Int. J. Mol. Sci. 2020, 21,
8458. [CrossRef] [PubMed]
39. Ghazy, E.; Kumar, A.; Barani, M.; Kaur, I.; Rahdar, A.; Behl, T. Scrutinizing the therapeutic and diagnostic potential of nan-
otechnology in thyroid cancer: Edifying drug targeting by nano-oncotherapeutics. J. Drug Deliv. Sci. Technol. 2021, 61, 102221.
[CrossRef]
40. Ghazy, E.; Rahdar, A.; Barani, M.; Kyzas, G.Z. Nanomaterials for Parkinson disease: Recent progress. J. Mol. Struct. 2020, 129698.
[CrossRef]
41. Hajizadeh, M.R.; Maleki, H.; Barani, M.; Fahmidehkar, M.A.; Mahmoodi, M.; Torkzadeh-Mahani, M. In vitro cytotoxicity assay of
D-limonene niosomes: An efficient nano-carrier for enhancing solubility of plant-extracted agents. Res. Pharm. Sci. 2019, 14, 448.
[PubMed]
42. Hasanein, P.; Rahdar, A.; Barani, M.; Baino, F.; Yari, S. Oil-in-water microemulsion encapsulation of antagonist drugs prevents
renal ischemia-reperfusion injury in rats. Appl. Sci. 2021, 11, 1264. [CrossRef]
43. Mukhtar, M.; Bilal, M.; Rahdar, A.; Barani, M.; Arshad, R.; Behl, T.; Brisc, C.; Banica, F.; Bungau, S. Nanomaterials for diagnosis
and treatment of brain cancer: Recent updates. Chemosensors 2020, 8, 117. [CrossRef]
44. Nikazar, S.; Barani, M.; Rahdar, A.; Zoghi, M.; Kyzas, G.Z. Photo- and magnetothermally responsive nanomaterials for therapy,
controlled drug delivery and imaging applications. ChemistrySelect 2020, 5, 12590–12609. [CrossRef]
45. Abdal Dayem, A.; Hossain, M.K.; Lee, S.B.; Kim, K.; Saha, S.K.; Yang, G.-M.; Choi, H.Y.; Cho, S.-G. The role of reactive oxygen
species (ROS) in the biological activities of metallic nanoparticles. Int. J. Mol. Sci. 2017, 18, 120. [CrossRef]
46. Singh, J.; Dutta, T.; Kim, K.-H.; Rawat, M.; Samddar, P.; Kumar, P. ‘Green’ synthesis of metals and their oxide nanoparticles:
Applications for environmental remediation. J. Nanobiotechnol. 2018, 16, 84. [CrossRef]
47. Arshad, R.; Sohail, M.F.; Sarwar, H.S.; Saeed, H.; Ali, I.; Akhtar, S.; Hussain, S.Z.; Afzal, I.; Jahan, S.; Shahnaz, G. ZnO-NPs
embedded biodegradable thiolated bandage for postoperative surgical site infection: In vitro and in vivo evaluation. PLoS ONE
2019, 14, e0217079. [CrossRef] [PubMed]
Nanomaterials 2021, 11, 546 17 of 21
48. Gour, A.; Jain, N.K. Advances in green synthesis of nanoparticles. Artif. Cells Nanomed. Biotechnol. 2019, 47, 844–851. [CrossRef]
49. Bayat, M.; Chudinova, E.; Zargar, M.; Lyashko, M.; Louis, K.; Adenew, F.K. Phytoassisted green synthesis of zinc oxide
nanoparticles and its antibacterial and antifungal activity. Res. Crop. 2019, 20, 725–730.
50. Kamran, U.; Bhatti, H.N.; Iqbal, M.; Nazir, A. Green synthesis of metal nanoparticles and their applications in different fields: A
review. Z. Phys. Chem. 2019, 233, 1325–1349. [CrossRef]
51. Akbarzadeh, F.; Motaghi, M.; Chauhan, N.P.S.; Sargazi, G. A novel synthesis of new antibacterial nanostructures based on
Zn-MOF compound: Design, characterization and a high performance application. Heliyon 2020, 6, e03231. [CrossRef] [PubMed]
52. Sargazi, G.; Afzali, D.; Mostafavi, A.; Shadman, A.; Rezaee, B.; Zarrintaj, P.; Saeb, M.R.; Ramakrishna, S.; Mozafari, M.
Chitosan/polyvinyl alcohol nanofibrous membranes: Towards green super-adsorbents for toxic gases. Heliyon 2019, 5, e01527.
[CrossRef] [PubMed]
53. Liang, H.; Nacharaju, P.; Friedman, A.; Friedman, J.M. Nitric oxide generating/releasing materials. Future Sci. OA 2015, 1, FSO54.
[CrossRef] [PubMed]
54. Quinn, J.F.; Whittaker, M.R.; Davis, T.P. Delivering nitric oxide with nanoparticles. J. Control. Release 2015, 205, 190–205. [CrossRef]
55. Behera, B.; Vishnu, G.A.; Chatterjee, S.; Sreekumar, N.; Nagabhushan, A.; Rajendran, N.; Prathik, B.; Pandya, H.J. Emerging
technologies for antibiotic susceptibility testing. Biosens. Bioelectron. 2019, 142, 111552. [CrossRef]
56. Barani, M.; Bilal, M.; Rahdar, A.; Arshad, R.; Kumar, A.; Hamishekar, H.; Kyzas, G.Z. Nanodiagnosis and nanotreatment of
colorectal cancer: An overview. J. Nanopart. Res. 2021, 23, 1–25. [CrossRef]
57. Barani, M.; Bilal, M.; Sabir, F.; Rahdar, A.; Kyzas, G.Z. Nanotechnology in ovarian cancer: Diagnosis and treatment. Life Sci. 2020,
266, 118914. [CrossRef] [PubMed]
58. Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Nematollahi, M.H. Lawsone-loaded niosome and its antitumor activity in MCF-7
breast cancer cell line: A nano-herbal treatment for cancer. DARU J. Pharm. Sci. 2018, 26, 11–17. [CrossRef]
59. Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Adeli-Sardou, M. Evaluation of carum-loaded niosomes on breast cancer cells:
Physicochemical properties, in vitro cytotoxicity, flow cytometric, DNA fragmentation and cell migration assay. Sci. Rep. 2019, 9,
1–10. [CrossRef] [PubMed]
60. Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Lohrasbi-Nejad, A.; Nematollahi, M.H. A new formulation of hydrophobin-coated
niosome as a drug carrier to cancer cells. Mater. Sci. Eng. C 2020, 113, 110975. [CrossRef] [PubMed]
61. Kwizera, E.A.; O’Connor, R.; Vinduska, V.; Williams, M.; Butch, E.R.; Snyder, S.E.; Chen, X.; Huang, X. Molecular detection and
analysis of exosomes using surface-enhanced Raman scattering gold nanorods and a miniaturized device. Theranostics 2018, 8,
2722. [CrossRef]
62. Song, T.-T.; Wang, W.; Meng, L.-L.; Liu, Y.; Jia, X.-B.; Mao, X. Electrochemical detection of human ferritin based on gold nanorod
reporter probe and cotton thread immunoassay device. Chin. Chem. Lett. 2017, 28, 226–230. [CrossRef]
63. Barani, M.; Mukhtar, M.; Rahdar, A.; Sargazi, G.; Thysiadou, A.; Kyzas, G.Z. Progress in the application of nanoparticles and
graphene as drug carriers and on the diagnosis of brain infections. Molecules 2021, 26, 186. [CrossRef]
64. Barani, M.; Nematollahi, M.H.; Zaboli, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Pardakhty, A.; Karam, G.A. In silico and in vitro
study of magnetic niosomes for gene delivery: The effect of ergosterol and cholesterol. Mater. Sci. Eng. C 2019, 94, 234–246.
[CrossRef] [PubMed]
65. Barani, M.; Sabir, F.; Rahdar, A.; Arshad, R.; Z Kyzas, G. Nanotreatment and nanodiagnosis of prostate cancer: Recent updates.
Nanomaterials 2020, 10, 1696. [CrossRef] [PubMed]
66. Barani, M.; Torkzadeh-Mahani, M.; Mirzaei, M.; Nematollahi, M.H. Comprehensive evaluation of gene expression in negative
and positive trigger-based targeting niosomes in HEK-293 cell line. Iran. J. Pharm. Res. IJPR 2020, 19, 166.
67. Bilal, M.; Barani, M.; Sabir, F.; Rahdar, A.; Kyzas, G.Z. Nanomaterials for the treatment and diagnosis of Alzheimer’s disease: An
overview. NanoImpact 2020, 20, 100251. [CrossRef]
68. Zheng, L.; Cai, G.; Wang, S.; Liao, M.; Li, Y.; Lin, J. A microfluidic colorimetric biosensor for rapid detection of Escherichia coli
O157: H7 using gold nanoparticle aggregation and smart phone imaging. Biosens. Bioelectron. 2019, 124, 143–149. [CrossRef]
69. Russell, C.; Welch, K.; Jarvius, J.; Cai, Y.; Brucas, R.; Nikolajeff, F.; Svedlindh, P.; Nilsson, M. Gold nanowire based electrical DNA
detection using rolling circle amplification. ACS Nano 2014, 8, 1147–1153. [CrossRef]
70. Das, S.S.; Bharadwaj, P.; Bilal, M.; Barani, M.; Rahdar, A.; Taboada, P.; Bungau, S.; Kyzas, G.Z. Stimuli-responsive polymeric
nanocarriers for drug delivery, imaging, and theragnosis. Polymers 2020, 12, 1397. [CrossRef] [PubMed]
71. Davarpanah, F.; Yazdi, A.K.; Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M. Magnetic delivery of antitumor carboplatin by using
PEGylated-Niosomes. DARU J. Pharm. Sci. 2018, 26, 57–64. [CrossRef] [PubMed]
72. Ebrahimi, A.K.; Barani, M.; Sheikhshoaie, I. Fabrication of a new superparamagnetic metal-organic framework with core-shell
nanocomposite structures: Characterization, biocompatibility, and drug release study. Mater. Sci. Eng. C 2018, 92, 349–355.
[CrossRef] [PubMed]
73. Finucane, T.E. “Urinary tract infection”—Requiem for a heavyweight. J. Am. Geriatr. Soc. 2017, 65, 1650–1655. [CrossRef]
[PubMed]
74. Okarska-Napierała, M.; Wasilewska, A.; Kuchar, E. Urinary tract infection in children: Diagnosis, treatment, imaging–Comparison
of current guidelines. J. Pediatr. Urol. 2017, 13, 567–573. [CrossRef] [PubMed]
Nanomaterials 2021, 11, 546 18 of 21
75. Thomas-White, K.J.; Gao, X.; Lin, H.; Fok, C.S.; Ghanayem, K.; Mueller, E.R.; Dong, Q.; Brubaker, L.; Wolfe, A.J. Urinary
microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int. Urogynecol. J. 2018, 29, 1797–1805.
[CrossRef] [PubMed]
76. Behzadi, P.; Behzadi, E.; Pawlak-Adamska, E.A. Urinary tract infections (UTIs) or genital tract infections (GTIs)? It’s the
diagnostics that count. GMS Hyg. Infect. Control 2019. [CrossRef]
77. Davenport, M.; Mach, K.E.; Shortliffe, L.M.D.; Banaei, N.; Wang, T.-H.; Liao, J.C. New and developing diagnostic technologies for
urinary tract infections. Nat. Rev. Urol. 2017, 14, 296–310. [CrossRef] [PubMed]
78. Kranz, J.; Schmidt, S.; Lebert, C.; Schneidewind, L.; Mandraka, F.; Kunze, M.; Helbig, S.; Vahlensieck, W.; Naber, K.; Schmiemann,
G. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of
uncomplicated urinary tract infections in adult patients. Part II: Therapy and prevention. Urol. Int. 2018, 100, 271–278. [CrossRef]
79. Claeys, K.C.; Blanco, N.; Morgan, D.J.; Leekha, S.; Sullivan, K.V. Advances and challenges in the diagnosis and treatment of
urinary tract infections: The need for diagnostic stewardship. Curr. Infect. Dis. Rep. 2019, 21, 11. [CrossRef] [PubMed]
80. Coulthard, M.G. Using urine nitrite sticks to test for urinary tract infection in children aged < 2 years: A meta-analysis. Pediatr.
Nephrol. 2019, 34, 1283–1288.
81. Masajtis-Zagajewska, A.; Nowicki, M. New markers of urinary tract infection. Clin. Chim. Acta 2017, 471, 286–291. [CrossRef]
82. Taylor, R.A.; Moore, C.L.; Cheung, K.-H.; Brandt, C. Predicting urinary tract infections in the emergency department with
machine learning. PLoS ONE 2018, 13, e0194085. [CrossRef]
83. Chu, C.M.; Lowder, J.L. Diagnosis and treatment of urinary tract infections across age groups. Am. J. Obstet. Gynecol. 2018, 219,
40–51. [CrossRef] [PubMed]
84. Rubab, M.; Shahbaz, H.M.; Olaimat, A.N.; Oh, D.-H. Biosensors for rapid and sensitive detection of Staphylococcus aureus in
food. Biosens. Bioelectron. 2018, 105, 49–57. [CrossRef] [PubMed]
85. Nasseri, B.; Soleimani, N.; Rabiee, N.; Kalbasi, A.; Karimi, M.; Hamblin, M.R. Point-of-care microfluidic devices for pathogen
detection. Biosens. Bioelectron. 2018, 117, 112–128. [CrossRef] [PubMed]
86. Kishimoto, M.; Tsuchiaka, S.; Rahpaya, S.S.; Hasebe, A.; Otsu, K.; Sugimura, S.; Kobayashi, S.; Komatsu, N.; Nagai, M.; Omatsu, T.
Development of a one-run real-time PCR detection system for pathogens associated with bovine respiratory disease complex. J.
Vet. Med. Sci. 2017, 79, 517–523. [CrossRef]
87. Hong, D.K.; Blauwkamp, T.A.; Kertesz, M.; Bercovici, S.; Truong, C.; Banaei, N. Liquid biopsy for infectious diseases: Sequencing
of cell-free plasma to detect pathogen DNA in patients with invasive fungal disease. Diagn. Microbiol. Infect. Dis. 2018, 92,
210–213. [CrossRef]
88. Caracciolo, G.; Vali, H.; Moore, A.; Mahmoudi, M. Challenges in molecular diagnostic research in cancer nanotechnology. Nano
Today 2019, 27, 6–10. [CrossRef]
89. Syedmoradi, L.; Daneshpour, M.; Alvandipour, M.; Gomez, F.A.; Hajghassem, H.; Omidfar, K. Point of care testing: The impact of
nanotechnology. Biosens. Bioelectron. 2017, 87, 373–387. [CrossRef] [PubMed]
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